Your session is about to expire
← Back to Search
Zanidatamab with Standard-of-care Therapy Arm for Breast Cancer
Study Summary
This trial aims to test the effectiveness and safety of a combination of drugs called Zanidatamab and CisGem, with or without another drug called a PD-1/L1 inhibitor,
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the enrollment phase of this medical study currently ongoing?
"Indeed, as per the details on clinicaltrials.gov, this research trial is actively seeking eligible participants. The study was initially posted on March 1st, 2024 and had its most recent update on February 21st, 2024. A total of 286 individuals are sought from two designated locations."
What is the current size of the patient cohort being observed in this clinical investigation?
"Affirmative. Documentation on clinicaltrials.gov indicates that this medical investigation is currently seeking eligible participants. The trial was initially posted on March 1st, 2024, and the most recent update occurred on February 21st, 2024. A total of 286 individuals are sought for enrollment at two distinct locations."
Has the combination of Zanidatamab with standard-of-care therapy arm been granted approval by the FDA?
"Our research team at Power has rated the safety of Zanidatamab in conjunction with Standard-of-care Therapy Arm as a 3 on our scale. This assessment aligns with it being a Phase 3 trial, implying existing efficacy data and robust safety evidence from prior phases."
Share this study with friends
Copy Link
Messenger